SOPHiA GENETICS Reports Q1 2025 Financial Results

SOPHiA GENETICS ( (SOPH) ) has shared an update.

On May 6, 2025, SOPHiA GENETICS SA released its unaudited interim condensed consolidated financial statements for the three months ending March 31, 2025. The company reported a revenue increase to $17.8 million from $15.8 million in the same period last year. Despite the revenue growth, the company faced a net loss of $17.4 million, attributed to high operating costs, including research and development and selling expenses. This financial update reflects the company’s ongoing investment in expanding its market presence and technological capabilities, which may impact its short-term profitability but aims to strengthen its long-term industry positioning.

Spark’s Take on SOPH Stock

According to Spark, TipRanks’ AI Analyst, SOPH is a Neutral.

SOPHiA GENETICS is in a challenging financial position with negative profitability and high cash burn, but it shows potential growth in revenue and customer acquisition. Technical analysis is mixed, with bearish trends but no extreme conditions. The valuation is unattractive due to negative earnings. However, there is optimism from the recent earnings call, with positive guidance and strategic growth initiatives. The overall score is influenced by the strong potential for future growth but tempered by current financial weaknesses.

To see Spark’s full report on SOPH stock, click here.

More about SOPHiA GENETICS

SOPHiA GENETICS SA is a company in the biotechnology industry, specializing in data-driven medicine with a focus on genomic analysis. The company provides software-as-a-service (SaaS) solutions that enable healthcare institutions to leverage data analytics for precision medicine, enhancing the diagnosis and treatment of diseases.

YTD Price Performance: -1.57%

Average Trading Volume: 55,617

Technical Sentiment Signal: Buy

Current Market Cap: $202.5M

For detailed information about SOPH stock, go to TipRanks’ Stock Analysis page.